These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 37584204)

  • 1. Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study).
    Namikawa K; Ito T; Yoshikawa S; Yoshino K; Kiniwa Y; Ohe S; Isei T; Takenouchi T; Kato H; Mizuhashi S; Fukushima S; Yamamoto Y; Inozume T; Fujisawa Y; Yamasaki O; Nakamura Y; Asai J; Maekawa T; Funakoshi T; Matsushita S; Nakano E; Oashi K; Kato J; Uhara H; Miyagawa T; Uchi H; Hatta N; Tsutsui K; Maeda T; Matsuya T; Yanagisawa H; Muto I; Okumura M; Ogata D; Yamazaki N
    Cancer Med; 2023 Sep; 12(17):17967-17980. PubMed ID: 37584204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
    Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
    Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
    Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
    Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
    Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
    Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
    Pires da Silva I; Zakria D; Ahmed T; Trojanello C; Dimitriou F; Allayous C; Gerard C; Zimmer L; Lo S; Michielin O; Lebbe C; Mangana J; Ascierto PA; Johnson DB; Carlino M; Menzies A; Long G
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF
    van Breeschoten J; Wouters MWJM; Hilarius DL; Haanen JB; Blank CU; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Blokx WAM; Tije BJT; Veldt AAMV; Vreugdenhil A; Boers-Sonderen MJ; van den Eertwegh AJM
    Br J Cancer; 2021 Mar; 124(7):1222-1230. PubMed ID: 33495600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
    Devji T; Levine O; Neupane B; Beyene J; Xie F
    JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
    Ma VT; Daignault-Newton S; Waninger JJ; Journey S; Chopra Z; Tezel A; Redman BG; Fecher LA; Green MD; Alva AS; Lao CD
    Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapy in Advanced Melanoma With Rare
    Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
    J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
    Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
    Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
    JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
    Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
    Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
    Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
    Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
    ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.
    Nakamura Y; Namikawa K; Kiniwa Y; Kato H; Yamasaki O; Yoshikawa S; Maekawa T; Matsushita S; Takenouchi T; Inozume T; Nakai Y; Fukushima S; Saito S; Otsuka A; Fujimoto N; Isei T; Baba N; Matsuya T; Tanaka R; Kaneko T; Onishi M; Kuwatsuka Y; Nagase K; Onuma T; Nomura M; Umeda Y; Yamazaki N
    Eur J Cancer; 2022 Nov; 176():78-87. PubMed ID: 36194906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
    Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
    Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
    Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
    Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line immunotherapy versus targeted therapy in patients with
    Pavlick AC; Zhao R; Lee CH; Ritchings C; Rao S
    Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.